[Treatment of septicemia due to gram negative bacilli (salmonellosis excluded)].
D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002228:Carbenicillin / Q000627:therapeutic use; D002509:Cephaloridine / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000188:drug therapy; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D007710:Klebsiella Infections / Q000188:drug therapy; D009268:Nalidixic Acid / Q000627:therapeutic use; D010403:Penicillin Resistance; D011379:Prognosis; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D012293:Rifampin / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009268:Nalidixic Acid; D007612:Kanamycin; D000667:Ampicillin; D002228:Carbenicillin; D002509:Cephaloridine; D002512:Cephalothin; D012293:Rifampin; D003091:Colistin
Le traitement des septicémies à bacilles gram négatif.